'''Taranabant''' (codenamed '''MK-0364''') is a [[cannabinoid receptor type 1]] [[inverse agonist]] that was investigated as a potential treatment for [[obesity]] due to its [[anorectic]] effects.<ref>Armstrong HE, Galka A, Lin LS, Lanza TJ Jr, Jewell JP, Shah SK, et al. "Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists." ''Bioorganic & Medicinal Chemistry Letters''. 2007 Apr 15;'''17'''(8):2184-7. {{PMID|17293109}}. {{doi|10.1016/j.bmcl.2007.01.087}}</ref><ref>Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, et al. "Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents." ''Journal of Pharmacology and Experimental Therapeutics''. 2007 Jun;'''321'''(3):1013-22. {{PMID|17327489}}. {{doi|10.1124/jpet.106.118737}}</ref> It was discovered by [[Merck & Co.]]

 
In October 2008, Merck has stopped its [[Clinical trials#Phase III|phase III]] [[clinical trials]] with the drugs due to high level of [[central nervous system|central]] side effects, mainly [[depression (mood)|depression]] and [[anxiety]].<ref name="urlMerck News Item">{{cite web |url=http://www.merck.com/newsroom/press_releases/research_and_development/2008_1002.html |title=Press release by Merck |work= |accessdate=October 2008}}</ref><ref name="pmid20157323">{{cite journal |vauthors=Aronne LJ, Tonstad S, Moreno M, Gantz I, Erondu N, Suryawanshi S, Molony C, Sieberts S, Nayee J, Meehan AG, Shapiro D, Heymsfield SB, Kaufman KD, Amatruda JM |title=A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study |journal=International Journal of Obesity (2005) |volume=34 |issue=5 |pages=919–35 |date=May 2010 |pmid=20157323 |doi=10.1038/ijo.2010.21 |url=}}</ref><ref name="pmid20518807">{{cite journal |vauthors=Kipnes MS, Hollander P, Fujioka K, Gantz I, Seck T, Erondu N, Shentu Y, Lu K, Suryawanshi S, Chou M, Johnson-Levonas AO, Heymsfield SB, Shapiro D, Kaufman KD, Amatruda JM |title=A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes |journal=Diabetes, Obesity & Metabolism |volume=12 |issue=6 |pages=517–31 |date=June 2010 |pmid=20518807 |doi=10.1111/j.1463-1326.2009.01188.x |url=}}</ref><ref name="pmid20212496">{{cite journal |vauthors=Proietto J, Rissanen A, Harp JB, Erondu N, Yu Q, Suryawanshi S, Jones ME, Johnson-Levonas AO, Heymsfield SB, Kaufman KD, Amatruda JM |title=A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study |journal=International Journal of Obesity (2005) |volume=34 |issue=8 |pages=1243–54 |date=August 2010 |pmid=20212496 |doi=10.1038/ijo.2010.38 |url=}}</ref>
